Overview Dividends

(PGNY) Progyny - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74340E1038

Fertility, Benefits, Pharmacy,

PGNY EPS (Earnings per Share)

EPS Growth (3Y CAGR): 14.25%
EPS Trend (3Y Correlation): 38.5%

PGNY Revenue

Revenue Growth (3Y CAGR): 19.20%
Revenue Trend (3Y Correlation): 90.1%

Description: PGNY Progyny

Progyny Inc (NASDAQ:PGNY) is a US-based healthcare services company. The firms business model is centered around providing fertility benefits to employees, which is a rapidly growing segment in the healthcare industry.

Key drivers of PGNYs financial performance include the increasing demand for fertility services, the growing awareness and acceptance of fertility treatments, and the companys ability to negotiate favorable pricing with providers. The companys revenue growth is likely driven by the increasing adoption of its services by employers and health plans.

To evaluate PGNYs performance, we can look at key performance indicators (KPIs) such as revenue growth rate, member acquisition rate, and average revenue per member. The companys ability to retain members and increase revenue per member will be crucial in driving long-term growth. Additionally, metrics such as the number of treatment cycles, live birth rates, and patient satisfaction will provide insights into the companys operational performance.

From a financial perspective, PGNYs valuation multiples, such as the P/E ratio of 39.46, suggest that the market is pricing in significant growth expectations. The forward P/E ratio of 14.43 indicates a potential decrease in earnings growth rate in the future. The companys Return on Equity (RoE) of 11.80% is a respectable metric, indicating that PGNY is generating profits from shareholder equity.

Economic drivers that may impact PGNYs business include changes in healthcare policy, the competitive landscape of the fertility benefits market, and demographic trends such as the increasing age of first-time mothers. The companys ability to adapt to these changes and maintain its competitive edge will be crucial in driving long-term success.

PGNY Stock Overview

Market Cap in USD	2,024m
Sub-Industry	Health Care Services
IPO / Inception	2019-10-25

PGNY Stock Ratings

Growth Rating	-25.9%
Fundamental	77.0%
Dividend Rating	-
Return 12m vs S&P 500	-18.7%
Analyst Rating	3.80 of 5

PGNY Dividends

Currently no dividends paid

PGNY Growth Ratios

Growth Correlation 3m	45.1%
Growth Correlation 12m	62.9%
Growth Correlation 5y	-73.8%
CAGR 5y	-18.09%
CAGR/Max DD 3y	-0.26
CAGR/Mean DD 3y	-0.62
Sharpe Ratio 12m	1.16
Alpha	-23.91
Beta	0.994
Volatility	41.85%
Current Volume	801.6k
Average Volume 20d	825.7k
Stop Loss	21.7 (-3.6%)
Signal	-2.12

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (53.1m TTM) > 0 and > 6% of Revenue (6% = 74.5m TTM)

FCFTA 0.25 (>2.0%) and ΔFCFTA 0.53pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 30.11% (prev 31.50%; Δ -1.39pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.27 (>3.0%) and CFO 202.0m > Net Income 53.1m (YES >=105%, WARN >=100%)

Net Debt (-107.0m) to EBITDA (82.7m) ratio: -1.29 <= 3.0 (WARN <= 3.5)

Current Ratio 2.70 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (89.6m) change vs 12m ago -8.38% (target <= -2.0% for YES)

Gross Margin 22.34% (prev 22.08%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 170.2% (prev 162.2%; Δ 8.01pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

error: Interest Coverage Ratio cannot be calculated (needs EBITDA TTM and Interest Expense TTM)

Altman Z'' 5.46

(A) 0.49 = (Total Current Assets 594.4m - Total Current Liabilities 220.4m) / Total Assets 761.0m

(B) 0.23 = Retained Earnings (Balance) 176.5m / Total Assets 761.0m

(D) 0.72 = Book Value of Equity 176.7m / Total Liabilities 245.9m

Total Rating: 5.46 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 77.00

1. Piotroski 6.0pt = 1.0

2. FCF Yield 10.88% = 5.0

3. FCF Margin 15.31% = 3.83

4. Debt/Equity 0.06 = 2.50

5. Debt/Ebitda 0.35 = 2.41

6. ROIC - WACC 1.60% = 2.01

7. RoE 11.55% = 0.96

8. Rev. Trend 90.15% = 4.51

9. Rev. CAGR 19.20% = 2.40

10. EPS Trend 38.53% = 0.96

11. EPS CAGR 14.25% = 1.42

What is the price of PGNY shares?

As of September 13, 2025, the stock is trading at USD 22.51 with a total of 801,637 shares traded.
Over the past week, the price has changed by -0.18%, over one month by +3.35%, over three months by +4.45% and over the past year by -3.18%.

Is Progyny a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, Progyny (NASDAQ:PGNY) is currently (September 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 77.00 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PGNY is around 18.65 USD . This means that PGNY is currently overvalued and has a potential downside of -17.15%.

Is PGNY a buy, sell or hold?

Progyny has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold PGNY.

Strong Buy: 4
Buy: 0
Hold: 6
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the PGNY price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	28.3	25.5%
Analysts Target Price	28.3	25.5%
ValueRay Target Price	21	-6.8%

Last update: 2025-09-05 04:55

PGNY Fundamental Data Overview

Market Cap USD = 2.02b (2.02b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 305.1m USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 39.8983
P/E Forward = 11.9474
P/S = 1.6297
P/B = 3.9291
Beta = 1.325
Revenue TTM = 1.24b USD
EBIT TTM = 78.7m USD
EBITDA TTM = 82.7m USD
Long Term Debt = 25.5m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 3.12m USD (from shortTermDebt, last quarter)
Debt = 28.6m USD (Calculated: Short Term 3.12m + Long Term 25.5m)
Net Debt = -107.0m USD (from netDebt column, last quarter)
Enterprise Value = 1.75b USD (2.02b + Debt 28.6m - CCE 305.1m)
Interest Coverage Ratio = unknown (Ebit TTM 78.7m / Interest Expense TTM 0.0)
FCF Yield = 10.88% (FCF TTM 190.2m / Enterprise Value 1.75b)
FCF Margin = 15.31% (FCF TTM 190.2m / Revenue TTM 1.24b)
Net Margin = 4.28% (Net Income TTM 53.1m / Revenue TTM 1.24b)
Gross Margin = 22.34% ((Revenue TTM 1.24b - Cost of Revenue TTM 964.5m) / Revenue TTM)
Tobins Q-Ratio = 9.89 (Enterprise Value 1.75b / Book Value Of Equity 176.7m)
Interest Expense / Debt = 2.47% (Interest Expense 706.0k / Debt 28.6m)
Taxrate = 34.69% (28.9m / 83.2m)
NOPAT = 51.4m (EBIT 78.7m * (1 - 34.69%))
Current Ratio = 2.70 (Total Current Assets 594.4m / Total Current Liabilities 220.4m)
Debt / Equity = 0.06 (Debt 28.6m / last Quarter total Stockholder Equity 515.0m)
Debt / EBITDA = 0.35 (Net Debt -107.0m / EBITDA 82.7m)
Debt / FCF = 0.15 (Debt 28.6m / FCF TTM 190.2m)
Total Stockholder Equity = 459.8m (last 4 quarters mean)
RoA = 6.98% (Net Income 53.1m, Total Assets 761.0m )
RoE = 11.55% (Net Income TTM 53.1m / Total Stockholder Equity 459.8m)
RoCE = 16.21% (Ebit 78.7m / (Equity 459.8m + L.T.Debt 25.5m))
RoIC = 11.17% (NOPAT 51.4m / Invested Capital 459.8m)
WACC = 9.57% (E(2.02b)/V(2.05b) * Re(9.68%)) + (D(28.6m)/V(2.05b) * Rd(2.47%) * (1-Tc(0.35)))
Shares Correlation 3-Years: -33.33 | Cagr: -0.97%
Discount Rate = 9.68% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 76.31% ; FCFE base≈182.5m ; Y1≈225.1m ; Y5≈384.1m
Fair Price DCF = 56.87 (DCF Value 4.89b / Shares Outstanding 86.0m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: 90.15 | Revenue CAGR: 19.20%
Rev Growth-of-Growth: -9.10
EPS Correlation: 38.53 | EPS CAGR: 14.25%
EPS Growth-of-Growth: -33.93

Additional Sources for PGNY Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle